ESTRO 2024 - Abstract Book
S1351
Clinical - Head & neck
ESTRO 2024
Keywords: Artificial Intelligence, Autocontouring
References:
1. Franzese C, Dei D, Lambri N, Teriaca MA, Badalamenti M, Crespi L, Tomatis S, Loiacono D, Mancosu P, Scorsetti M. Enhancing Radiotherapy Workflow for Head and Neck Cancer with Artificial Intelligence: A Systematic Review. J Pers Med. 2023 Jun 2;13(6):946. doi: 10.3390/jpm13060946. PMID: 37373935; PMCID: PMC10301548.
2. Segedin B, Petric P. Uncertainties in target volume delineation in radiotherapy - are they relevant and what can we do about them? Radiol Oncol (2016) 50(3):254 – 625. doi: 10.1515/raon-2016-0023
3. National Institute of Clinical Excellence: Artificial intelligence technologies to aid contouring for radiotherapy treatment planning: early value assessment, published 27 September 2023. Available from: https://www.nice.org.uk/guidance/hte11 4. Doolan PJ, Charalambous S, Roussakis Y, Leczynski A, Peratikou M, Benjamin M et al. A clinical evaluation of the performance of five commercial artificial intelligence contouring systems for radiotherapy. Front Oncol. 2023;13:1213068. Published 2023 Aug 4. doi:10.3389/fonc.2023.1213068
1897
Digital Poster
SBRT for lung-only oligometastatic head and neck squamous cell carcinoma: long-term clinical outcome
Viola Salvestrini, Ilaria Bonaparte, Carlotta Becherini, Isacco Desideri, Niccolò Bertini, Pietro Garlatti, Icro Meattini, Anna Peruzzi, Andrea Romei, Carolina Orsatti, Chiara Mattioli, Luca Burchini, Lucia Angelini, Luisa Caprara, Maria Grazia Carnevale, Pierluigi Bonomo, Lorenzo Livi
Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
Purpose/Objective:
Oligometastatic disease in head and neck squamous cell carcinoma (HNSCC) is an atypical scenario. Local ablative treatments are the most adopted strategies although no evidence-based recommendations are currently available. The purpose of our analysis was to update and report on long-term clinical outcomes of a cohort of HNSCC patients treated with stereotactic body radiotherapy (SBRT) for lung-only oligometastatic disease.
Material/Methods:
Patients with 1 to 5 pulmonary metastases were included. The oligometastatic pattern was defined as “de novo” or “oligoprogressive” according to ESTRO/EORTC consensus recommendations. We evaluated time to progression
Made with FlippingBook - Online Brochure Maker